Empyema Treated With tPA & DNAse
Phase 3
Withdrawn
- Conditions
- Empyema
- Registration Number
- NCT01862458
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Brief Summary
The objective of this study is to scientifically evaluate a new substrate for fibrinolysis compared to our standard tPA.
The hypothesis, driven by a recent prospective trial, is that tPA may benefit from the addition of DNAse.
The primary outcome variable between the two techniques will be length of hospitalization after initiation of treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients less than 18 years of age requiring an intervention for empyema by one of the following:
- Septation or loculation seen on ultrasound or computed tomography or
- Greater than 10,000 white blood cells identified on pleural tap
Exclusion Criteria
- Immunodeficiency process
- Secondary diagnosis or condition that will keep them in the hospital beyond the empyema
- Existing contraindications to chest tube
- Documented allergy to one of the study medications
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Length of stay 3 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Children's Mercy Hospital
🇺🇸Kansas City, Missouri, United States
Children's Mercy Hospital🇺🇸Kansas City, Missouri, United States